Kaplan, Jeffrey
Askanase, Anca
Chu, David
Abdellatif, Abdul
Basu, Dhiman
Mirsaeidi, Mehdi
Funding for this research was provided by:
Mallinckrodt Pharmaceuticals
Article History
Accepted: 23 August 2023
First Online: 4 October 2023
Declarations
:
: All authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article and contributed to the conception or design of the work; acquisition, analysis, or interpretation of data; drafting or critically revising the work for important intellectual content; and final approval of the manuscript.
: This review paper was funded by Mallinckrodt Pharmaceuticals.
: Anca Askanase has been an investigator or consultant for AbbVie, Amgen, AstraZeneca, Aurinia, Bristol Myers Squibb, Celgene, Eli Lilly, Idorsia, Janssen, Genentech, GSK, Mallinckrodt, Pfizer, and UCB. Abdul Abdellatif has been a consultant and paid speaker for Horizon Therapeutics. David Chu has received consulting fees or a research grant from Aldeyra, Bausch and Lomb, Kriya, Mallinckrodt, and Santen. Dhiman Basu and Mehdi Mirsaeidi have no disclosures to report. Jeffrey Kaplan has received fees as a speaker or consultant for Alexion, Allergan, Amgen, Biogen, Biohaven, Bristol Myers Squibb, EMD Serono, Genentech, Genzyme, Horizon, Impel, Janssen, Lundbeck, Mallinckrodt, Merck, Novartis, and Teva.
: Not applicable.
: Not applicable.
: Not applicable.
: Data and study material are available on reasonable request from the corresponding author.
: Not applicable.